Controlled Substances and Precursor Program

(December 2018)

Description of program

Health Canada's Controlled Substances Directorate, part of the Opioid Response Team, acts as the Canadian competent authority with respect to the United Nations Drug Control Conventions. Its mission is to improve and protect the health of Canadians by preventing or minimizing the negative impacts associated with controlled and other psychoactive substances, while ensuring access to controlled substances and precursors for legitimate purposes.

Why was a Privacy Impact Assessment (PIA) completed?

It was determined that the Controlled Substances and Precursor Program required a PIA because it uses personal information as part of a decision‐making process that directly affects the individual and because of substantial modifications to existing programs or activities where personal information is used, or intended to be used, for an administrative purpose.

The PIA examines the privacy-related risks of the Controlled Substances and Precursor Program and proposes methods to lower these risks.

More information

This PIA focused on Health Canada's collection, use, disclosure and retention and disposition of personal information involved in the Controlled Substances and Precursor Program's business processes.

The PIA recommended mitigation actions in the following risk areas: the absence of a Privacy Notice Statement and an attestation on the reporting forms and the absence of a Personal Information Bank.

If you would like more information about this PIA please contact:

Health Canada / Public Health Agency of Canada Privacy Management Division (PMD) 11 Holland Avenue
Tower A, 5th Floor, Suite 513 Ottawa, ON
K1A 0K9
Mail Stop 3005
Ottawa, Ontario K1A 0K9
E-mail:privacy-vie.privee@hc-sc.gc.ca
Telephone: 613-946-3179
Fax: 613-941-4541
Teletypewriter: 1-800-465-7735 (Service Canada)